Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers

Bernardes, Miguel; Vieira, T.; Martins, Maria João; Lucas, Raquel; Costa, Lúcia; Pereira, Jorge; Ventura, Francisco; Martins, Elisabete

doi:10.1155/2017/6509754

Cited by 15 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All the specimens were measured in duplicate, according to the manufacturer's instructions and then averaged. OPG, DKK-1, RANKL, and sclerostin were determined as previously described [40]. Serotonin was measured using a kit from Labor Diagnostika Nord GmbH & Co, KG (Nordhorn, Germany); the intra-and inter-assay coefficients of variation were 3.9-5.4 and 6.0%, respectively.…”

Section: Laboratory Measurementsmentioning

confidence: 99%

Serum serotonin levels and bone in rheumatoid arthritis patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

In rheumatoid arthritis (RA), a disease characterized by bone loss, increased levels of serotonin have been reported. Recent studies have demonstrated a role for circulating serotonin as a regulator of osteoblastogenesis, inhibiting bone formation. Thus, we measured serum serotonin levels (SSL) in a Portuguese sample of 205 RA patients and related these to anthropometric variables, disease parameters, serum bone biomarkers, and bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry at several sites (total proximal femur, lumbar spine, left hand, and left second proximal phalange). SSL were inversely associated with body mass index (BMI) in RA women (r = - 0.218; p = 0.005), independent of exposure to biologics and/or bisphosphonates. Among biologic naïves, there was an inverse association between SSL and osteoprotegerin in RA women (r = - 0.260; p = 0.022). Serum β-CTX and dickkopf-1 were strongly associated with SSL in RA men not treated with bisphosphonates (r = 0.590; p < 0.001/r = 0.387; p = 0.031, respectively). There was also an inverse association between SSL and sclerostin in RA men (r = - 0.374; p < 0.05), stronger among biologic naïve or bisphosphonates-unexposed RA men. In crude models, SSL presented as a significant negative predictor of total proximal femur BMD in RA women as well as in postmenopausal RA women. After adjustment for BMI, disease duration, and years of menopause, SSL remained a significant negative predictor of total proximal femur BMD only in postmenopausal RA women. Our data reinforce a role, despite weak, for circulating serotonin in regulating bone mass in RA patients, with some differences in terms of gender and anatomical sites.

show abstract

Section: Laboratory Measurementsmentioning

confidence: 99%

Serum serotonin levels and bone in rheumatoid arthritis patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lipid profile, glucose, insulin, CRP, ESR, rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (ACPA), homocysteine, uric acid, creatinine, 25(OH) vitamin D 3 , folic acid, intact parathyroid hormone, osteocalcin, beta‐carboxy‐terminal cross‐linking telopeptide of type I collagen (beta‐CTX), B‐type natriuretic peptide (BNP), OPG, receptor activator of nuclear factor–kappa B ligand (RANKL), dickkopf‐1 (Dkk‐1) and sclerostin levels were analyzed in a fasting blood sample. OPG, RANKL, Dkk‐1 and sclerostin were measured as previously described . Homeostasis model assessment for insulin resistance (HOMA‐IR) was calculated, using the formula: HOMA‐IR = (fasting insulin [mUI/L] × fasting glucose [mg/dL]/405) …”

Section: Methodsmentioning

confidence: 99%

“…CV comorbidities are indeed a major cause of mortality in RA patients and the relative risk of myocardial infarction is 1.5, against the general population . However, prediction of CV events in RA is far from being ideal, as has been shown in different studies . A deeper understanding of the mechanisms involved in vascular remodeling, including coronary calcification, is fundamental for the development of efficacious prevention strategies of CV disease in RA.…”

Section: Introductionmentioning

confidence: 99%

“…biological markers, bone mineral density, cardiovascular diseases, heart diseases, rheumatoid arthritis telopeptide of type I collagen (beta-CTX), B-type natriuretic peptide (BNP), OPG, receptor activator of nuclear factor-kappa B ligand (RANKL), dickkopf-1 (Dkk-1) and sclerostin levels were analyzed in a fasting blood sample. OPG, RANKL, Dkk-1 and sclerostin were measured as previously described 4. Homeostasis model assessment for insulin resistance (HOMA-IR) was calculated, using the formula: HOMA-IR = (fasting insulin [mUI/L] × fasting glucose [mg/dL]/405) 30.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Coronary artery calcium score in female rheumatoid arthritis patients: Associations with apolipoproteins and disease biomarkers

et al. 2019

Self Cite

View full text Add to dashboard Cite

Aims and methods In rheumatoid arthritis (RA), cardiovascular (CV) comorbidities are a major cause of mortality. Coronary Calcium Score (CCS) assessed by computed tomography has been associated with RA prognosis. In this work, we aimed to assess CCS in female RA patients and determine CCS association with different clinical, laboratory and imaging disease parameters. Results We evaluated 60 female patients, with a mean age of 53.6 ± 10.4 years, a mean Disease Activity Score of 28 joints (DAS28) (4v) and Health Assessment Questionnaire (HAQ) of 4.542 ± 1.317 and 1.488 ± 0.631, respectively, and a disease duration of 14.7 ± 10.3 years. Mean CCS value was 35.192 ± 117.786. CCS > 10 was significantly associated with CV risk factors (age: odds ratio [OR] = 1.120; P = .002, body mass index [BMI] ≥ 25 kg/m2: OR = 0.271; P = .025, high‐density lipoprotein [HDL]: OR = 0.011; P = .025, low‐density lipoprotein/ HDL ratio: OR = 2.084; P = .030, apolipoprotein A1 [ApoA1]: OR = 0.965; P = .014, apolipoprotein B/ApoA1 [ApoB/ApoA1] ratio: OR = 59.834; P = .011, homocysteine: OR = 1.287; P = .045, diabetes: OR = 10.400; P = .043, and anti‐diabetic therapy: OR = 10.667, P = .041), disease parameters (C‐reactive protein [CRP]: OR = 1.038; P = .046, DAS[4v]: OR = 1.900; P = .009, DAS28[4v; CRP]: OR = 1.700; P = .019, DAS[3v]: OR = 1.947; P = .010, DAS28[3v; CRP]: OR = 1.696; P = .022, HAQ: OR = 3.299; P = .023, erosion score: OR = 1.015; P = .012, and total modified Sharp/van der Heijde Score: OR = 1.008; P = .035), biomarkers (osteoprotegerin: OR = 1.505; P = .022), and bone mineral density (femoral: OR = 0.005; P = .018, lumbar spine: OR = 0.001; P = .002, left hand: OR = 7.9 × 10−9; P = .005, and osteoporosis: OR = 6.628; P = .007). After adjustment for age and BMI, significant associations were maintained with ApoA1, ApoB/ApoA1 ratio, homocysteine, CRP, DAS(4v), DAS(4v; CRP), DAS(3v) and DAS(3v; CRP). A sensitivity analysis undertaken after excluding the 6 diabetics yielded similar results. Conclusions Our work reinforces the hypothesis that in RA, CCS may be a useful tool in CV risk assessment, particularly valuable in poorer controlled patients with certain lipoprotein profiles.

show abstract

“…OPG is a "fake" competitive receptor, binding to RANKL, preventing it from binding to RANK and signaling, causing the opposite effect -preventing bone loss [10]. The disorders of OPG / RANKL system not only affect bone metabolism but also play an important role in cardiovascular, inflammatory, cancer and autoimmune diseases [13][14][15]. Most available data on that issue come from the research in adults.…”

Section: Introductionmentioning

confidence: 99%

Serum Osteoprotegrin, Total Srankl and Their Determinants in Adolescents with Type 1 Diabetes

2018

IJDMD

View full text Add to dashboard Cite

Aim: The aim of the study was to evaluate the levels of osteoprotegerin (OPG), receptor activator of nuclear factor –κB ligand (s-RANKL), OPG/sRANKL ratio and sRANKL/OPG ratio in adolescent patients with type 1 diabetes mellitus (T1DM), and to assess their correlation with the following factors: patients’ gender, age, metabolic control, age of the diagnosis and duration of the disease. Patients and Methods: 60 T1DM patients (32 girls and 28 boys, mean±SD age: 15.0±1.9 years, diabetes duration: 5.1±3.9 years, age of the diagnosis: 9.9±3.9 years, HbA1c: 7.9±1.4%) and 18 healthy matched controls were included. Osteoprotegerin and total sRANKL (free and bound sRANKL) were measured by ELISA (enzyme-linked immunosorbent assay). Results: There were no statistically significant differences in serum OPG levels between patients and controls (51.56±12.05 vs. 50.98±13.55pmol/L, p=0.84. No correlation betweengender and OPG levels both in the study and control group has been reported, although OPG levels were significantly lower in diabetic boys (2.59±0.67 pmol/L) than in control boys (3.30±1.01 pmol/l) (p = 0.031). Tetryl analysis (qualifications) dependent on OPG levels has demonstrated statistically significant correlation between the study group and clinical factors such as: gender, age of the diagnosis and duration of the disease, but not with the age. Only the tendency toward correlation between OPG and metabolic control of diabetes (p=0.093) has been observed. No statistically significant differences in sRANKL levels between the study group and controls has been identified. In patients with T1DM no correlation between RANKL levels and clinical factors such as gender, duration of the disease, age of the diagnosis and metabolic control has been reported. Only negative correlation between RANKL level and patients’ age (p = 0.002) has been observed. No correlationbetween OPG and RANKL levels has been demonstrated. No statistically significant differences in OPG/RANKL ratios between the study group and controls has been reported, the only significant difference in these ratios was observed between control females and males (p = 0.019), but not in the study group. A positive correlation between OPG/RANKL ratio and OPG level with the age has been demonstrated in the study group.

show abstract

Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers

Cited by 15 publications

References 40 publications

Serum serotonin levels and bone in rheumatoid arthritis patients

Serum serotonin levels and bone in rheumatoid arthritis patients

Coronary artery calcium score in female rheumatoid arthritis patients: Associations with apolipoproteins and disease biomarkers

Serum Osteoprotegrin, Total Srankl and Their Determinants in Adolescents with Type 1 Diabetes

Contact Info

Product

Resources

About